NASDAQ:GNPX News | QuoteStream

tradingview

Genprex partners with Roche Diagnostics to validate TROP2 biomarker for NSCLC, aims to finish validation by end of 2026

Genprex announced a collaboration with Roche Diagnostics to validate TROP2 and PTEN biomarkers to refine patient selection for NSCLC clinical trials.Key Highlights:Original SEC Filing: Genprex, Inc. [ GNPX ] - 8-K - Aug. 03, 2026This is an AI-powered summary. It may contain inaccuracies. Consider v…

TradingView en_IN 3/8/2026, 07:03 pm GMT+8

StocksUS

GNPX

tradingview

Genprex Disclosed Failure to Satisfy a Continued Listing Rule or Standard

On July 29, 2026, a Nasdaq Hearings Panel granted the company an exception to continue its Nasdaq listing related to the $1.00 minimum bid price rule (Rule 5550(a)(2)). Genprex must demonstrate compliance by July 29, 2026 and then maintain a closing bid of at least $1.00 for each trading day throug…

TradingView en_IN 31/7/2026, 04:33 am GMT+8

StocksUS